1. Home
  2. QH vs BOLD Comparison

QH vs BOLD Comparison

Compare QH & BOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

QH

Quhuo Limited American Depository Shares

N/A

Current Price

$3.12

Market Cap

8.0M

ML Signal

N/A

Logo Boundless Bio Inc.

BOLD

Boundless Bio Inc.

N/A

Current Price

$2.40

Market Cap

54.5M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
QH
BOLD
Founded
2012
2018
Country
China
United States
Employees
N/A
N/A
Industry
Business Services
Sector
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
8.0M
54.5M
IPO Year
2019
2024

Fundamental Metrics

Financial Performance
Metric
QH
BOLD
Price
$3.12
$2.40
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
2.5K
★ 80.9K
Earning Date
12-01-2026
11-10-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 32.47
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$2.86
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.07
$0.96
52 Week High
$12.81
$3.16

Technical Indicators

Market Signals
Indicator
QH
BOLD
Relative Strength Index (RSI) 46.11 42.88
Support Level $2.76 $2.32
Resistance Level $4.07 $2.65
Average True Range (ATR) 0.12 0.09
MACD 0.06 0.01
Stochastic Oscillator 52.38 9.52

Price Performance

Historical Comparison
QH
BOLD

About QH Quhuo Limited American Depository Shares

Quhuo Ltd is a gig economy platform focusing on local life services in China. It provide tech-enabled, end-to-end operational solutions to consumer service businesses, including on-demand delivery solutions, mobility service solutions, housekeeping and accommodation solutions, and other services. Its three operating segments, include (i) on-demand delivery solutions, (ii) mobility service solutions, and (iii) housekeeping and accommodation solutions and other services. It generates maximum of its revenue from the on-demand delivery solutions segment.

About BOLD Boundless Bio Inc.

Boundless Bio Inc is a clinical-stage oncology company. It is focused on developing cancer therapeutics that address the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Using its proprietary Spyglass platform, the company identifies targets essential for ecDNA functionality, then designs and develops small-molecule drugs called ecDNA-directed therapies (ecDTx) to inhibit those targets. Its main ecDTx candidate under development, BBI-940, is a novel, oral, selective degrader that has demonstrated potent anti-tumor activity across a range of cancer cell lines and mouse xenograft models, including single-agent tumor regressions.

Share on Social Networks: